Free press releases distribution network?

Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Despite Safety Concerns Anti-Obesity Drug Market is Predicted to Unveil A Blockbuster by 2012 - Report Buyer, has added a new report predicting that there will be at least one anti-obesity blockbuster by 2012 and multi-billion revenues for the segment by early next decade
Despite Safety Concerns Anti-Obesity Drug Market is Predicted to Unveil A Blockbuster by 2012

 

PRZOOM - /newswire/ - London, United Kingdom, 2007/10/22 - Report Buyer, has added a new report predicting that there will be at least one anti-obesity blockbuster by 2012 and multi-billion revenues for the segment by early next decade.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“Anti-Obesity Treatments 2007-2012 - A Blockbuster Target Market” finds that by 2010, almost 50% of children in North America and 38 % of those in the European Union will be overweight. Obesity is also the most common nutritional disorder in Western, industrialised countries. These statistics lead analysts to predict that the anti-obesity drug treatment market offers unique opportunities for pharmaceutical companies who are looking to target successful markets.

The report critically examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market, especially in the U.S and Europe where obesity is being described as an epidemic and a "public health time-bomb". It finds that there are several factors aiding the potential success of anti-obesity drugs, notably the increase in Government funding to tackle the problem, and also growing acceptance of the drug-class from stakeholders.

Analysts however say that it will not be all smooth sailing for pharmaceutical companies as there are many hurdles that need to be overcome before drugs are launched successfully. For instance, there is a growing demand from healthcare authorities and practitioners that anti-obesity drugs are efficacious, safe and cost-effective. A case in point is the recent rejection by the Food and Drug Administration advisory panel of Sanofi-Aventis' obesity drug Zimulti because of concerns it may increase suicidal thinking and depression. However, some experts predict that anti-obesity drugs will eventually work as reliably as anti-hypertensives and lipid regulators.

The study critically examines the market for anti-obesity drugs concentrating on types of anti-obesity treatments available as well as key industrial players in the sector. It forecasts to 2012 and identifies future leading therapeutic agents.

“Anti-Obesity Treatments 2007-2012 - A Blockbuster Target Market” is available from Report Buyer. For more information, please visit the website.

Report Buyer product ID: VIS00060

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Despite Safety Concerns Anti-Obesity Drug Market is Predicted to Unveil A Blockbuster by 2012

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Urmila Doraswami 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Report Buyer Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today